Defence Therapeutics Inc Class A

As of March 31, 2026, Defence Therapeutics Inc Class A carries a market capitalization of 24.94M, placing it among publicly traded companies globally. Its enterprise value stands at 24.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Defence Therapeutics Inc Class A has 75.59M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Defence Therapeutics Inc Class A maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Defence Therapeutics Inc Class A's stock has declined approximately 51.92% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.31.

As of March 31, 2026, Defence Therapeutics Inc Class A holds 1.84M in cash and equivalents against 973,045.90 in total debt, resulting in a net debt position of -863,914.34. Total book value stands at 3.37M, with working capital of 1.43M providing operational flexibility.